This is a summary of the European public assessment report (EPAR) for Exforge HCT. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Exforge HCT.
Therapeutic Indication
### Therapeutic indication Treatment of essential hypertension as substitution therapy in adult patients whose blood pressure is adequately controlled on the combination of amlodipine, valsartan and hydrochlorothiazide (HCT), taken either as three single-component formulations or as a dual-component and a single-component formulation.
Therapeutic Area (MeSH)
ATC Code
C09DX01
ATC Item
valsartan, amlodipine and hydrochlorothiazide
Pharmacotherapeutic Group
Agents acting on the renin-angiotensin system
Active Substance (Summary)
INN / Common Names
EMA Name
Exforge HCT
Medicine Name
Exforge HCT
Aliases
N/ANo risk management plan link.
